Book a Meeting

ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody (CAT#: BioBet-CB-030LX) Datasheet

Target
CD19
Isotype
IgG1
Description
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody is a glycosylation-modified anti- therapeutic antibody.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD19 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD19
Full Name
CD19 molecule
Background
Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation.
Alternative Names
CD19; CD19 molecule; B4; CVID3; B-lymphocyte antigen CD19; differentiation antigen CD19; T-cell surface antigen Leu-12; B-lymphocyte surface antigen B4
Gene ID
930
UniProt ID
P15391
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
Loncastuximab
Host
Humanized
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody is derived from clone Loncastuximab, which is a Humanized monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD19, and it is intended for the research of Diffuse large B-cell lymphoma.
Indication
Diffuse large B-cell lymphoma

Similar to the parental antibody Loncastuximab, ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody targets to the antigen CD19, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.

Related Products

ADCC-Enhanced Anti-Human CD19 (Tafasitamab) Antibody (CAT#: BioBet-CB-003LX)
Highly Galactosylated Anti-CD19 (Taplitumomab paptox) Antibody (CAT#: BioBet-GA-103ZP)
Highly Galactosylated Anti-CD19 (Blinatumomab) Antibody (CAT#: BioBet-GA-010ZP)
Non-Fucosylated Anti-Human CD19 (R005-1) Therapeutic Antibody (CAT#: BioBet-1694ZP)
Non-Fucosylated Anti-Human CD19 (GBR 401) Therapeutic Antibody (CAT#: BioBet-1794ZP)
Highly Galactosylated Anti-CD19 (denintuzumab mafodotin) Antibody (CAT#: BioBet-GA-107ZP)
Non-fucosylated Anti-Human CD19 (Denintuzumab) Therapeutic Antibody (CAT#: BioBet-105ZP)
BetterBet™ Anti-CD19 Half-Life Extended Antibody (CAT#: AES-0622-ZP1032)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.